[go: up one dir, main page]

 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (4,389)

Search Parameters:
Keywords = 3T3-L1 cells

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
20 pages, 10282 KiB  
Article
Molecular Integrative Study on Inhibitory Effects of Pentapeptides on Polymerization and Cell Toxicity of Amyloid-β Peptide (1–42)
by Lianmeng Ye, Nuela Manka’a Che Ajuyo, Zhongyun Wu, Nan Yuan, Zhengpan Xiao, Wenyu Gu, Jiazheng Zhao, Yechun Pei, Yi Min and Dayong Wang
Curr. Issues Mol. Biol. 2024, 46(9), 10160-10179; https://doi.org/10.3390/cimb46090606 (registering DOI) - 14 Sep 2024
Viewed by 138
Abstract
Alzheimer’s Disease (AD) is a multifaceted neurodegenerative disease predominantly defined by the extracellular accumulation of amyloid-β (Aβ) peptide. In light of this, in the past decade, several clinical approaches have been used aiming at developing peptides for therapeutic use in AD. The use [...] Read more.
Alzheimer’s Disease (AD) is a multifaceted neurodegenerative disease predominantly defined by the extracellular accumulation of amyloid-β (Aβ) peptide. In light of this, in the past decade, several clinical approaches have been used aiming at developing peptides for therapeutic use in AD. The use of cationic arginine-rich peptides (CARPs) in targeting protein aggregations has been on the rise. Also, the process of peptide development employing computational approaches has attracted a lot of attention recently. Using a structure database containing pentapeptides made from 20 L-α amino acids, we employed molecular docking to sort pentapeptides that can bind to Aβ42, then performed molecular dynamics (MD) analyses, including analysis of the binding stability, interaction energy, and binding free energy to screen ligands. Transmission electron microscopy (TEM), circular dichroism (CD), thioflavin T (ThT) fluorescence detection of Aβ42 polymerization, MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay, and the flow cytometry of reactive oxygen species (ROS) were carried out to evaluate the influence of pentapeptides on the aggregation and cell toxicity of Aβ42. Two pentapeptides (TRRRR and ARRGR) were found to have strong effects on inhibiting the aggregation of Aβ42 and reducing the toxicity of Aβ42 secreted by SH-SY5Y cells, including cell death, reactive oxygen species (ROS) production, and apoptosis. Full article
Show Figures

Figure 1

Figure 1
<p>Molecular docking of the five pentapeptides with Aβ<sub>42</sub>. (<b>A</b>) Binding of TRRRR with Aβ<sub>42</sub>. (<b>B</b>) Binding of RRRWR with Aβ<sub>42</sub>. (<b>C</b>) Binding of RRRDS with Aβ<sub>42</sub>. (<b>D</b>) Binding of ARRGR with Aβ<sub>42</sub>. (<b>E</b>) Binding of TRRAR with Aβ<sub>42</sub>. For clarity, only three strands taken from Aβ<sub>42</sub> pentamer are shown in this figure. The magenta mesh represents the molecular surface of the pentapeptides, and the gray mesh represents the boundary of van der Waal’s force. Arrows indicate the hydrogen bonds. TRRRR: Threonine-arginine-arginine-arginine-arginine; RRRWR: Arginine-arginine-arginine-tryptophan-arginine; RRRDS: Arginine-arginine-arginine-aspartic acid-serine; ARRGR: Alanine-arginine-arginine-glycine-arginine; TRRAR: Threonine-arginine-arginine-alanine-arginine.</p>
Full article ">Figure 2
<p>The binding stability and interaction energy of the pentapeptides at different hydrophobic regions. (<b>A</b>) The binding stability of pentapeptides to Aβ<sub>42</sub> pentamer. (<b>B</b>) The interaction energy between Aβ<sub>42</sub> pentamer and the pentapeptides. RMSD: The root mean square deviation of the positions of the heavy elements of a pentapeptide. The interaction energy is the algebraic sum of Lennard-Jones and Coulombic potential energy. TRRRR: Threonine-arginine-arginine-arginine-arginine; RRRWR: Arginine-arginine-arginine-tryptophan-arginine; RRRDS: Arginine-arginine-arginine-aspartic acid-serine; ARRGR: Alanine-arginine-arginine-glycine-arginine; TRRAR: Threonine-arginine-arginine-alanine-arginine.</p>
Full article ">Figure 3
<p>Variation in the lengths of hydrogen bonds formed between the pentapeptides and Aβ<sub>42</sub>. (<b>A</b>) ARRGR and Aβ<sub>42</sub>. (<b>B</b>) RRRDS and Aβ<sub>42</sub>. (<b>C</b>) RRRWR and Aβ<sub>42</sub>. (<b>D</b>) TRRAR and Aβ<sub>42</sub>. (<b>E</b>) TRRRR and Aβ<sub>42</sub>. TRRRR: Threonine-arginine-arginine-arginine-arginine; RRRWR: Arginine-arginine-arginine-tryptophan-arginine; RRRDS: Arginine-arginine-arginine-aspartic acid-serine; ARRGR: Alanine-arginine-arginine-glycine-arginine; TRRAR: Threonine-arginine-arginine-alanine-arginine.</p>
Full article ">Figure 4
<p>Variation in the angles of hydrogen bonds formed the pentapeptides and Aβ<sub>42</sub>. (<b>A</b>) <b>A</b>RRGR and Aβ<sub>42</sub>. (<b>B</b>) RRRDS and Aβ<sub>42</sub>. (<b>C</b>) RRRWR and Aβ<sub>42</sub>. (<b>D</b>) TRRAR and Aβ<sub>42</sub>. (<b>E</b>) TRRRR and Aβ<sub>42</sub>. TRRRR: Threonine-arginine-arginine-arginine-arginine; RRRWR: Arginine-arginine-arginine-tryptophan-arginine; RRRDS: Arginine-arginine-arginine-aspartic acid-serine; ARRGR: Alanine-arginine-arginine-glycine-arginine; TRRAR: Threonine-arginine-arginine-alanine-arginine.</p>
Full article ">Figure 5
<p>Binding free energy between the pentapeptides and Aβ<sub>42</sub>. (<b>A</b>) TRRRR and Aβ<sub>42</sub>. (<b>B</b>) RRRDS and Aβ<sub>42</sub>. (<b>C</b>) ARRGR and Aβ<sub>42</sub>. (<b>D</b>) RRRWR and Aβ<sub>42</sub>. (<b>E</b>) TRRAR and Aβ<sub>42</sub>. TRRRR: Threonine-arginine-arginine-arginine-arginine; RRRWR: Arginine-arginine-arginine-tryptophan-arginine; RRRDS: Arginine-arginine-arginine-aspartic acid-serine; ARRGR: Alanine-arginine-arginine-glycine-arginine; TRRAR: Threonine-arginine-arginine-alanine-arginine.</p>
Full article ">Figure 6
<p>Effects of pentapeptides on aggregation of Aβ<sub>42</sub> detected by ThT fluorescence assay. Results are expressed as means ± SD, <span class="html-italic">p</span> &lt; 0.01 among groups, tested by two-way ANOVA, n = 5.</p>
Full article ">Figure 7
<p>Effect of pentapeptides on aggregation of Aβ<sub>42</sub> detected by transmission electron microscopy. (<b>A</b>) Transmission electron microscopic images of 10 μM Aβ<sub>42</sub> before incubation. (<b>B</b>) The Atomic Fraction of Aβ<sub>42</sub> detected by HAADF-STEM imaging. (<b>C</b>) Transmission electron microscopic images of 10 μM Aβ<sub>42</sub> incubated for 48 h. (<b>D</b>) Transmission electron microscopic images of 10 μM Aβ<sub>42</sub> co-incubated with 40 μM TRRRR for 48 h. (<b>E</b>) Transmission electron microscopic image of 10 μM Aβ<sub>42</sub> co-incubated with 40 μM ARRGR for 48 h.</p>
Full article ">Figure 8
<p>Effects of TRRRR and ARRGR on Aβ<sub>42</sub> protein expression. Aβ<sub>42</sub><sup>–</sup>: SH-SY5Y cells not secreting Aβ<sub>42</sub>; Aβ<sub>42</sub><sup>+</sup>: SH-SY5Y cells secreting Aβ<sub>42</sub>. The results are expressed as means ± SD; ns: insignificant; ** <span class="html-italic">p</span> &lt; 0.01; the results were analyzed by one-way ANOVA, followed by the Tukey–Kramer test for multiple comparisons, with n = 3.</p>
Full article ">Figure 9
<p>Effects of TRRRR and ARRGR against cell toxicity of Aβ<sub>42</sub> secreted from SH-SY5Y. (<b>A</b>) The morphology of SH-SY5Y cells secreting Aβ<sub>42</sub>. Round-shaped cells with a bright edge are dying or dead. (<b>B</b>) Damaged cells detected with ethidium bromide, a nuclei acid tracer that cannot pass through an intact cell membrane. (<b>C</b>) Quantification of cell damage by using Image J. Results are expressed as means ± SD with ** <span class="html-italic">p</span> &lt; 0.01, and were analyzed by one-way ANOVA, followed by the Tukey–Kramer test for multiple comparisons, n = 3; ns: insignificant. In (<b>A</b>,<b>B</b>): (<b>a</b>) SH-SY5Y control cells that do not secrete Aβ<sub>42</sub>. (<b>b</b>) The control cells treated with TRRRR at 50 μM. (<b>c</b>) The control cells treated with ARRGR at 50 μM. (<b>d</b>) SH-SY5Y cells secreting Aβ<sub>42</sub>. (<b>e</b>) Aβ<sub>42</sub>-secreting SH-SY5Y cells treated with 10 μM TRRRR. (<b>f</b>) Aβ<sub>42</sub>-secreting SH-SY5Y cells treated with 10 μM ARRGR. (<b>g</b>) Aβ<sub>42</sub>-secreting SH-SY5Y cells treated with 50 μM TRRRR. (<b>h</b>) Aβ<sub>42</sub>-secreting SH-SY5Y cells treated with 50 μM ARRGR.</p>
Full article ">Figure 10
<p>Effects of the pentapeptides on ROS levels in SH-SY5Y cells secreting Aβ<sub>42</sub>. (<b>A</b>) ROS levels in the SH-SY5Y control cells that do not secrete Aβ<sub>42</sub>. (<b>B</b>) ROS levels in the control cells treated with 50 μM TRRRR. (<b>C</b>) ROS levels in the control cells treated with 50 μM ARRGR. (<b>D</b>) ROS levels in SH-SY5Y cells secreting Aβ<sub>42</sub>. (<b>E</b>) ROS levels in the Aβ<sub>42</sub>-secreting cells treated with 10 μM TRRRR. (<b>F</b>) ROS levels in the Aβ<sub>42</sub>-secreting cells treated with 10 μM ARRGR. (<b>G</b>) ROS levels in the Aβ<sub>42</sub>-secreting cells treated with 50 μM TRRRR. (<b>H</b>) ROS levels in the Aβ<sub>42</sub>-secreting cells treated with 50 μM ARRGR. (<b>I</b>) Overlay of the flow cytometry plots (<b>A</b>–<b>H</b>). (<b>J</b>) Quantification of the ROS levels in the cells. Results are expressed as means ± SD, ns: not significant, ** <span class="html-italic">p</span> &lt; 0.01, by one-way ANOVA, followed by the Tukey–Kramer test for multiple comparisons, with n = 3.</p>
Full article ">Figure 11
<p>Effects of pentapeptide on apoptosis of SY-SY5Y cells secreting Aβ<sub>42</sub>. (<b>A</b>) Apoptosis in the SH-SY5Y control cells that do not secrete Aβ<sub>42</sub>. (<b>B</b>) Apoptosis in the control cells treated with 50 μM TRRRR. (<b>C</b>) Apoptosis in the control cells treated with 50 μM ARRGR. (<b>D</b>) Apoptosis in SH-SY5Y cells secreting Aβ<sub>42</sub>. (<b>E</b>) Apoptosis in the Aβ<sub>42</sub>-secreting cells treated with 10 μM TRRRR. (<b>F</b>) Apoptosis in the Aβ<sub>42</sub>-secreting cells treated with 10 μM ARRGR. (<b>G</b>) Apoptosis in the Aβ<sub>42</sub>-secreting cells treated with 50 μM TRRRR. (<b>H</b>) Apoptosis in the Aβ<sub>42</sub>-secreting cells treated with 50 μM ARRGR. (<b>I</b>) Overlay of the flow cytometry plots (<b>A</b>–<b>H</b>). (<b>J</b>) Quantification of apoptosis in the cells. Results are expressed as means ± SD; ns: not significant, ** <span class="html-italic">p</span> &lt; 0.01; results were analyzed by one-way ANOVA, followed by the Tukey–Kramer test for multiple comparisons, with n = 3.</p>
Full article ">
17 pages, 3373 KiB  
Article
The Interactions of T Cells with Myeloid-Derived Suppressor Cells in Peripheral Blood Stem Cell Grafts
by Qingdong Guan, Scott G. Gilpin, James Doerksen, Lauren Bath, Tracy Lam, Yun Li, Pascal Lambert and Donna A. Wall
Cells 2024, 13(18), 1545; https://doi.org/10.3390/cells13181545 (registering DOI) - 14 Sep 2024
Viewed by 225
Abstract
The interaction of myeloid-derived suppressor cells (MDSCs) with T cells within G-CSF-mobilized peripheral blood stem cell (PBSC) grafts in patients undergoing autologous or allogeneic hematopoietic stem cell transplantation remains to be elucidated. Through studying allo- and auto-PBSC grafts, we observed grafts containing large [...] Read more.
The interaction of myeloid-derived suppressor cells (MDSCs) with T cells within G-CSF-mobilized peripheral blood stem cell (PBSC) grafts in patients undergoing autologous or allogeneic hematopoietic stem cell transplantation remains to be elucidated. Through studying allo- and auto-PBSC grafts, we observed grafts containing large numbers of T cells and MDSCs with intergraft variability in their percentage and number. T cells from autologous grafts compared to allografts expressed relative higher percentages of inhibitory receptors PD-1, CTLA-4, TIM-3, LAG-3, TIGIT and BTLA. Autograft T cells had decreased cell proliferation and IFN-γ secretion, which supported the possible presence of T cell exhaustion. On the contrary, graft monocytic MDSCs (M-MDSCs) expressed multiple inhibitory receptor ligands, including PD-L1, CD86, Galectin-9, HVEM and CD155. The expression of inhibitory receptor ligands on M-MDSCs was correlated with their corresponding inhibitory receptors on T cells in the grafts. Isolated M-MDSCs had the ability to suppress T cell proliferation and IFN-γ secretion and/or promote Treg expansion. Blocking the PD-L1-PD-1 signaling pathway partially reversed the functions of M-MDSCs. Taken together, our data indicated that T cells and M-MDSCs in PBSC grafts express complementary inhibitory receptor–ligand pairing, which may impact the quality of immune recovery and clinical outcome post transplantation. Full article
Show Figures

Figure 1

Figure 1
<p>A comparison of cellular compositions in allografts, lymphoma autografts and MM autografts. The percentages of CD34<sup>+</sup> stem cells, CD33<sup>+</sup>CD14<sup>+</sup>CD15<sup>−</sup>HLA-DR<sup>−/low</sup> M-MDSC, CD33<sup>+</sup>CD14<sup>−</sup>CD15<sup>+</sup> PMN-MDSC, CD33<sup>+</sup>CD14<sup>−</sup>CD15<sup>−</sup>HLA-DR<sup>−</sup> e-MDSC, CD3<sup>+</sup>T, CD3<sup>−</sup>CD56<sup>+</sup>NK, CD3<sup>+</sup>CD56<sup>+</sup>NKT, CD3<sup>+</sup>CD56<sup>−</sup>TCRαβ<sup>+</sup>CD4<sup>−</sup>CD8<sup>−</sup> DNTreg, CD3<sup>+</sup>CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup>Treg, CD19<sup>+</sup>B cells, and CD14<sup>+</sup>HLA-DR<sup>hi</sup> conventional monocytes in the grafts were evaluated by staining the graft cells using fluorescence labeled antibodies and analyzed by Flowjo software. (<b>A</b>) Percentages of cell subsets in the grafts. (<b>B</b>) Infusion dose of cell subsets in the grafts. *, <span class="html-italic">p</span> &lt; 0.05; **, <span class="html-italic">p</span> &lt; 0.01; ***, <span class="html-italic">p</span> &lt; 0.001.</p>
Full article ">Figure 2
<p>Characterization of T cells in the grafts. To evaluate the percentages of naïve, effector or memory T cells, fluorescence-labeled antibodies against CD45RA and CCR7 were added into the staining panel. To evaluate the proliferation and cytokine secretion of T cells in the grafts, sorted CD3<sup>+</sup>T cells from allografts and autografts were cultured for 5 days and then were stained with Ki67 to evaluate T cell proliferation, with fluorescence-labeled anti-IFN-γ for cytokine secretion. The expression of inhibitory receptors PD-1, CTLA-4, TIM-3, LAG-3, TIGIT and BTLA on CD4<sup>+</sup>T and CD8<sup>+</sup>T cells were evaluated by staining the graft cells using fluorescence-labeled antibodies. (<b>A</b>) Percentages of naïve, effector, central memory and effector memory T cells in the grafts. (<b>B</b>) The expression levels of Ki67 and IFN-γ in CD3<sup>+</sup>T cells of 10 allografts, 9 lymphoma autografts and 10 MM autografts. (<b>C</b>) The expression pattern of inhibitory receptors on T cells in the grafts. *, <span class="html-italic">p</span> &lt; 0.05; **, <span class="html-italic">p</span> &lt; 0.01; ***, <span class="html-italic">p</span> &lt; 0.001.</p>
Full article ">Figure 2 Cont.
<p>Characterization of T cells in the grafts. To evaluate the percentages of naïve, effector or memory T cells, fluorescence-labeled antibodies against CD45RA and CCR7 were added into the staining panel. To evaluate the proliferation and cytokine secretion of T cells in the grafts, sorted CD3<sup>+</sup>T cells from allografts and autografts were cultured for 5 days and then were stained with Ki67 to evaluate T cell proliferation, with fluorescence-labeled anti-IFN-γ for cytokine secretion. The expression of inhibitory receptors PD-1, CTLA-4, TIM-3, LAG-3, TIGIT and BTLA on CD4<sup>+</sup>T and CD8<sup>+</sup>T cells were evaluated by staining the graft cells using fluorescence-labeled antibodies. (<b>A</b>) Percentages of naïve, effector, central memory and effector memory T cells in the grafts. (<b>B</b>) The expression levels of Ki67 and IFN-γ in CD3<sup>+</sup>T cells of 10 allografts, 9 lymphoma autografts and 10 MM autografts. (<b>C</b>) The expression pattern of inhibitory receptors on T cells in the grafts. *, <span class="html-italic">p</span> &lt; 0.05; **, <span class="html-italic">p</span> &lt; 0.01; ***, <span class="html-italic">p</span> &lt; 0.001.</p>
Full article ">Figure 3
<p>The expression of inhibitory receptor ligands on M-MDSCs in the grafts. The expression of inhibitory receptor ligands PD-L1, CD86, Galectin-9, CD155 and HVEM were evaluated by staining the graft cells using fluorescence-labeled antibodies. Analysis was gated on M-MDSCs. *, <span class="html-italic">p</span> &lt; 0.05; **, <span class="html-italic">p</span> &lt; 0.01; ***, <span class="html-italic">p</span> &lt; 0.001.</p>
Full article ">Figure 4
<p>Morphology and immune regulatory function of M-MDSCs in the allografts, lymphoma and MM autografts. M-MDSCs were sorted from allografts, lymphoma and MM autografts using flow cytometer based on cell surface markers. The morphology of M-MDSCs was evaluated by HEMA-3 staining and then read via microscopy (200× magnification). By using CD3 negative selection kit, CD3<sup>+</sup>T cells were sorted from peripheral blood of third-party healthy donors or from PBSCs grafts of lymphoma or multiple myeloma patients. CD3<sup>+</sup>T cells were co-cultured with M-MDSCs at different ratios in the presence of anti-CD3/CD28 for 4–5 days. T cell proliferation, IFN-γ secretion and Treg expansion were evaluated. (<b>A</b>) Morphology and immune regulatory function of M-MDSCs sorted from allograft on third-party T cell proliferation, IFN-γ secretion and CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup>Treg expansion. (<b>B</b>) Morphology and immune regulatory function of M-MDSCs sorted from lymphoma autograft on autologous T cell proliferation, IFN-γ secretion and autologous CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup>Treg expansion. (<b>C</b>) Morphology and immune regulatory function of M-MDSCs sorted from MM autograft on autologous T cell proliferation and IFN-γ secretion. (<b>D</b>) Comparison of suppressive function of M-MDSCs sorted from allograft or autograft against the same third-party healthy donor T cells at a ratio of T:M-MDSC (1:0.4). *, <span class="html-italic">p</span> &lt; 0.05; **, <span class="html-italic">p</span> &lt; 0.01; ***, <span class="html-italic">p</span> &lt; 0.001. These results represent one of two to three independent experiments.</p>
Full article ">Figure 5
<p>M-MDSCs drive CD8<sup>+</sup>T cell exhaustion. M-MDSCs sorted from lymphoma autograft were co-cultured with sorted autologous CD3<sup>+</sup>T cells in the presence of anti-CD3/CD28 for 4–5 days. The T cell proliferation, expression of PD-1 and IFN-γ on CD8<sup>+</sup>T cells and CD4<sup>+</sup>T cells were evaluated. To block the interaction of PD-L1 with PD-1, anti-PD-L1 (10 μg/mL) was added into the co-culture system at the beginning. (<b>A</b>) The representative figures of expression of PD-1 and IFN-γ on CD8<sup>+</sup>T cells. (<b>B</b>) Effects of M-MDSCs on autologous T cell proliferation, effector T expansion and PD-1 expression. (<b>C</b>) The effects of anti-PD-L1 on the suppressive function of M-MDSCs sorted from lymphoma autograft. *, <span class="html-italic">p</span> &lt; 0.05; **, <span class="html-italic">p</span> &lt; 0.01; ***, <span class="html-italic">p</span> &lt; 0.001.</p>
Full article ">Figure 6
<p>Morphology and immune regulatory function of PMN-MDSCs in the allografts, lymphoma and MM autografts. The morphology of sorted PMN-MDSCs was evaluated by HEMA-3 staining and then read via microscopy (200× magnification). The CD3<sup>+</sup>T cells sorted from healthy third-party donor or autologous donor were co-cultured with PMN-MDSCs at different ratios in the presence of anti-CD3/CD28 for 4–5 days. T cell proliferation, IFN-γ secretion and Treg expansion were evaluated. (<b>A</b>) Morphology and immune regulatory function of PMN-MDSCs sorted from allograft on third-party T cell proliferation, IFN-γ secretion and CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup>Treg expansion. (<b>B</b>) Morphology and immune regulatory function of PMN-MDSCs sorted from lymphoma autograft on T cell proliferation, IFN-γ secretion and CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup>Treg expansion. (<b>C</b>) Morphology and immune regulatory function of PMN-MDSCs sorted from MM autograft on T cell proliferation and IFN-γ secretion. (<b>D</b>) Comparison of the suppressive function of M-MDSCs and PMN-MDSCs from the same graft at a ratio of T:M-MDSC (1:0.4). These results represent one of two to three independent experiments. *, <span class="html-italic">p</span> &lt; 0.05; **, <span class="html-italic">p</span> &lt; 0.01; ***, <span class="html-italic">p</span> &lt; 0.001.</p>
Full article ">
11 pages, 1587 KiB  
Article
Different Antigen-Specific CD4+ and CD8+ T-Cell Response against HCMV Proteins in Pregnant Women with Primary Infection and in Control Subjects with Remote Infection
by Federica Zavaglio, Piera d’Angelo, Chiara Fornara, Paola Zelini, Giuditta Comolli, Milena Furione, Alessia Arossa, Arsenio Spinillo, Daniele Lilleri and Fausto Baldanti
J. Clin. Med. 2024, 13(18), 5448; https://doi.org/10.3390/jcm13185448 - 13 Sep 2024
Viewed by 245
Abstract
Background/Objectives: Human cytomegalovirus (HCMV) is the most frequent cause of congenital infections. The HCMV-specific T-cell response in primary infection may help define reliable correlates of immune protection in pregnancy. In this study, the antigen-specific T-cell response against different HCMV proteins (IE-1, pp65, [...] Read more.
Background/Objectives: Human cytomegalovirus (HCMV) is the most frequent cause of congenital infections. The HCMV-specific T-cell response in primary infection may help define reliable correlates of immune protection in pregnancy. In this study, the antigen-specific T-cell response against different HCMV proteins (IE-1, pp65, gB, gHgLpUL128L) was investigated in pregnant women with primary infection and in control subjects with remote infection to identify possible components of a vaccine. Methods: Blood samples from 35 pregnant women with HCMV primary infection and 30 HCMV-seropositive healthy adult subjects with remote infection were tested. The antigen-specific T-cell response was measured using cytokine intracellular staining after stimulation with IE-1, pp65, gB and gHgLpUL128L peptides pool. Results: The pp65-specific CD4+ T-cell response was higher in pregnant women with HCMV primary infection at the late time point and in control subjects with remote infection, while the pregnant women at the early time point showed a higher gB-specific CD8+ T-cell response. Regarding the CD4+ and CD8+ T-cell phenotypes, we observed that HCMV-specific CD4+ and CD8+ T cells expressing CD45RA+ remained constant in pregnant women with primary infection at the early and late time points and in subjects with remote infection, while HCMV-specific CD4+ and CD8+ T cells expressing IL-7R+ or producing IL-2 were higher in control subjects with remote infection than in pregnant women with HCMV primary infection. Conclusions: The T-cell response was higher against gB in the early phase of infection and against pp65 in the late phase. Therefore, these proteins should be taken into consideration as candidates for a vaccine. Full article
(This article belongs to the Section Immunology)
Show Figures

Figure 1

Figure 1
<p>Percentage of HCMV-specific T cells producing IFN-γ after stimulation with IE-1, pp65, gB, gHgLpUL128L in pregnant women with HCMV primary infection at the early and the late time points, and in control subjects with HCMV remote infection. (<b>A</b>) Antigen-specific IFN-γ<sup>+</sup> CD4<sup>+</sup> T cells and (<b>B</b>) IFN-γ<sup>+</sup> CD8<sup>+</sup> T cells. Early time point: median: 60; (IQR49-65) days after onset infection. Late time point: median: 360; (IQR 356-412) days after onset infection. *** <span class="html-italic">p</span> &lt; 0.001. Dash lines divide the different peptides pool.</p>
Full article ">Figure 2
<p>Frequency of CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responders to HCMV peptide pools (IE-1, pp65, gB and gHgLpUL128L) detected in pregnant women with HCMV primary at the early and the late time point and in control subjects with HCMV remote infection. Percentage of responders to different numbers HCMV peptides pool (<b>A</b>,<b>B</b>) and frequencies of responders to IE-1, pp65, gB and gHgLpUL128L peptides pool (<b>C</b>,<b>D</b>), are reported. Early time point: median: 60; (IQR 49–65) days after onset infection. Late time point: median: 360; (IQR 356–412) days after onset infection. Dash lines divide the different peptides pool.</p>
Full article ">Figure 3
<p>IE1, pp65, gB and gHgLpUL128L-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells expressing (<b>A</b>,<b>B</b>) CD45RA<sup>+</sup>, (<b>C</b>,<b>D</b>) IL-7R<sup>+</sup> and (<b>E</b>,<b>F</b>) producing IL-2 in pregnant women with HCMV primary infection at the early and late time point and in subjects with remote infection. Early time point: median: 60; (IQR 49–65) days after onset infection. Late time point: median: 360; (IQR 356–412) days after onset infection. * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001. Dash lines divide the different peptides pool.</p>
Full article ">Figure 4
<p>CD4<sup>+</sup> and CD8<sup>+</sup> T-cell response to human cytomegalovirus (HCMV) peptides pool proteins (IE-1, pp65, gB and gHgLpUL128L) detected in 24 non-transmitting and 11 transmitting pregnant women at the early time point. (<b>A</b>) IFNγ<sup>+</sup> CD4<sup>+</sup> T cells. (<b>B</b>) IFNγ<sup>+</sup> CD8<sup>+</sup> T cells. Early time point: median: 60; (IQR 49–65) days after onset infection.</p>
Full article ">
12 pages, 891 KiB  
Article
Effect of Exogenous Melatonin on Performance and Mastitis in Dairy Cows
by Yunmeng Li, Zhiqiang Cheng, Wenting Ma, Yaqi Qiu, Tuo Liu, Bingyu Nan, Mengfei Li, Long Sun, Wentao Liu, Haina Yin, Caidie Wang, Xiaobin Li and Changjiang Zang
Vet. Sci. 2024, 11(9), 431; https://doi.org/10.3390/vetsci11090431 - 13 Sep 2024
Viewed by 273
Abstract
Mastitis is an important factor affecting the health of cows that leads to elevated somatic cell counts in milk, which can seriously affect milk quality and result in huge economic losses for the livestock industry. Therefore, the aim of this trial was to [...] Read more.
Mastitis is an important factor affecting the health of cows that leads to elevated somatic cell counts in milk, which can seriously affect milk quality and result in huge economic losses for the livestock industry. Therefore, the aim of this trial was to investigate the effect of melatonin on performance and mastitis in dairy cows. Forty-eight Holstein cows with a similar body weight (470 ± 10 kg), parity (2.75 ± 1.23), number of lactation days (143 ± 43 days), BCS (3.0–3.5), milk yield (36.80 ± 4.18 kg), and somatic cell count (300,000–500,000 cells/mL) were selected and randomly divided into four groups: control (CON group), trial Ⅰ (T80 group), trial Ⅱ (T120 group), and trial Ⅲ (T160 group). Twelve cows in trial groups I, II, and III were pre-dispensed 80, 120, and 160 mg of melatonin in edible glutinous rice capsules along with the basal ration, respectively, while the control group was fed an empty glutinous rice capsule along with the ration. The trial period was 37 days, which included a 7-day adaptive phase followed by a 30-day experimental period. At the end of the trial period, feeding was ended and the cows were observed for 7 days. Milk samples were collected on days 0, 7, 14, 21, 28, and 37 to determine the somatic cell number and milk composition. Blood samples were collected on days 0, 15, 30, and 37 of the trial to determine the serum biochemical indicators, antioxidant and immune indicators, and the amount of melatonin in the blood. The results showed that the somatic cell counts of lactating cows in the CON group were lower than those in the T120 group on days 14 (p < 0.05) and 28 (p < 0.01) at 1 week after melatonin cessation. The milk protein percentage and milk fat percentage of cows in the T120 group were higher than those in the CON group (p < 0.01). The total protein and globulin content in the T120 group were higher than those in the CON group (p < 0.01). In terms of antioxidant capacity and immunity, the cows 1 week after melatonin cessation showed higher superoxide dismutase activity and interleukin-10 contents (p < 0.01) compared with the CON group and lower malondialdehyde and tumor necrosis factor-alpha contents (p < 0.01) compared with the T120 group. The melatonin content in the T120 group was increased relative to that in the other groups. In conclusion, exogenous melatonin can increase the content of milk components, reduce the somatic cell count, and improve the antioxidant capacity and immune responses to a certain extent. Under the experimental conditions, 120 mg/day melatonin is recommended for mid- to late-lactation cows. Full article
(This article belongs to the Special Issue Effects of Nutrition on Ruminants Production Performance and Health)
Show Figures

Figure 1

Figure 1
<p>Trial design and grouping diagram.</p>
Full article ">Figure 2
<p>Effect of melatonin on somatic cell count in dairy cows.T80, trial 80 mg/day; T120, trial 120 mg/day; T160, trial 160 mg/day; SEM, standard error of mean; SCC, somatic cell count; CON, control with no MT; T80, T120, and T160, fed basal ration and 80 mg/day, 120 mg/day, or 160 mg/day of MT (Senrise Technology Co., Ltd., Anqing, China) per cow, respectively. In the figure, the same letter indicates no significant difference (<span class="html-italic">p</span> &gt; 0.05) and different lowercase or uppercase letters indicate significant differences (<span class="html-italic">p</span> &lt; 0.05; <span class="html-italic">p</span> &lt; 0.01).</p>
Full article ">
14 pages, 3144 KiB  
Article
Towards the Use of Lichens as a Source of Bioactive Substances for Topical Applications
by Izabela Baczewska, Barbara Hawrylak-Nowak, Martyna Zagórska-Dziok, Aleksandra Ziemlewska, Zofia Nizioł-Łukaszewska, Grzegorz Borowski and Sławomir Dresler
Molecules 2024, 29(18), 4352; https://doi.org/10.3390/molecules29184352 - 13 Sep 2024
Viewed by 178
Abstract
The increasing incidence of dermatological diseases prompts the search for new natural methods of treatments, and lichens, with their special symbiotic structure, are a little-known and promising source of biologically active substances. Seven lichen species, Cladonia unicialis (L.) Weber ex F.H. Wigg. (Cladoniaceae) [...] Read more.
The increasing incidence of dermatological diseases prompts the search for new natural methods of treatments, and lichens, with their special symbiotic structure, are a little-known and promising source of biologically active substances. Seven lichen species, Cladonia unicialis (L.) Weber ex F.H. Wigg. (Cladoniaceae), Evernia prunastri (L.) Ach. (Parmeliaceae), Hypogymnia physodes (L.) Nyl. (Parmaliaceae), Parmelia sulcata (Taylor) (Parmeliaceae), Physcia adscendens (Fr.) H. Olivier (Physciaceae), Pseudoevernia furfuracea (L.) Zopf (Parmeliaceae), and Xanthoria parietina (L.) Th. Fr. (Teloschistaceae), were used in our experiment. We identified different metabolites in the acetone extracts of all the lichen species. Based on the high-performance liquid chromatography analysis, the content of lichen substances in the extracts was evaluated. The impact of the individual lichen-specific reference substances, compared to the lichen extracts, on the viability of keratinocytes (HaCaT cell line) and fibroblasts (BJ cell line) and on the activity of selected skin-related enzymes was investigated. Our results revealed that only emodin anthrone at a concentration of 200 mg/L was cytotoxic to keratinocytes and fibroblasts in both cell viability assays. In turn, the C. uncialis extract was only cytotoxic to keratinocytes when used at the same concentration. The other tested treatments showed a positive effect on cell viability and no cytotoxicity or indeterminate cytotoxicity (shown in only one of the tests). Elastase and collagenase activities were inhibited by most of the lichen extracts. In turn, the individual lichen compounds (with the exception of evernic acid) generally had an undesirable stimulatory effect on hyaluronidase and collagenase activity. In addition, almost all the tested compounds and extracts showed anti-inflammatory activity. This suggests that some lichen compounds hold promise as potential ingredients in dermatological and skincare products, but their safety and efficacy require further study. The high cytotoxicity of emodin anthrone highlights its potential use in the treatment of hyperproliferative skin diseases such as psoriasis. Full article
(This article belongs to the Special Issue Medicinal Value of Natural Bioactive Compounds and Plant Extracts II)
Show Figures

Figure 1

Figure 1
<p>Photos of lichens used in the research: (<b>a</b>) <span class="html-italic">Cladonia uncialis</span>, (<b>b</b>) <span class="html-italic">Evernia prunastri</span>, (<b>c</b>) <span class="html-italic">Hypogymnia physodes</span>, (<b>d</b>) <span class="html-italic">Parmelia sulcata</span>, (<b>e</b>) <span class="html-italic">Physcia ascendens</span>, (<b>f</b>) <span class="html-italic">Pseudevernia furcuracea</span>, and (<b>g</b>) <span class="html-italic">Xanthoria parietina</span>.</p>
Full article ">Figure 2
<p>Structural formulae of the identified lichen metabolites belonging to four classes of lichen compounds.</p>
Full article ">Figure 3
<p>Effect of isolated compounds (ethyl orsellinate, physodic acid, physodalic acid, 3-hydroxyphysodic acid, atranorin, evernic acid, vulpinic acid, usnic acid, protocetraric acid, emodin anthrone, physcion) or lichen acetone extracts (<span class="html-italic">E. prunastri, H. physodes, P. sulcata, P. furfuracea, C. uncialis, P. adscendens, X. parietina</span>) at the concentration of 50 and 200 mg/L on the viability of keratinocytes (HaCaT) after 24 h of exposure determined by the Alamar blue assay (<b>a</b>) and the neutral red uptake assay (<b>b</b>). Data are mean ± SD (<span class="html-italic">n</span> = 3), * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001 compared to the control (dashed line, 100% of enzyme activity) (Dunnett test).</p>
Full article ">Figure 4
<p>Effect of isolated compounds (ethyl orsellinate, physodic acid, physodalic acid, 3-hydroxyphysodic acid, atranorin, evernic acid, vulpinic acid, usnic acid, protocetraric acid, emodin anthrone, physcion) or lichen acetone extracts (<span class="html-italic">E. prunastri, H. physodes, P. sulcata, P. furfuracea, C. uncialis, P. adscendens, X. parietina</span>) at the concentration of 50 or 200 mg/L on the viability of fibroblast cells (BJ) after 24 h of exposure determined by the Alamar blue assay (<b>a</b>) and the neutral red uptake assay (<b>b</b>). Data are mean ± SD (<span class="html-italic">n</span> = 3), * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001 compared to the control (dashed line, 100% of enzyme activity) (Dunnett test).</p>
Full article ">Figure 5
<p>Effect of 50 or 200 mg/L of isolated lichen compounds (ethyl orsellinate, physodic acid, physodalic acid, 3-hydroxyphysodic acid, atranorin, evernic acid, usnic acid, protocetraric acid, emodin anthrone, physcion, vulpinic acid) on COX-2 (<b>a</b>), elastase (<b>b</b>), hyaluronidase (<b>c</b>), and collagenase (<b>d</b>) activity in fibroblasts (BJ). Data are mean ± SD (<span class="html-italic">n</span> = 3), * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001 compared to the control (dashed line, 100% of enzyme activity) (Dunnett test).</p>
Full article ">Figure 6
<p>Effect of 50 or 200 mg/L of lichen raw extracts (<span class="html-italic">E. prunastri, H. physodes, P. sulcata, P. furfuracea, C. unicialis, P. adscendens, X. parietina</span>) on COX-2 (<b>a</b>), elastase (<b>b</b>), hyaluronidase (<b>c</b>), and collagenase (<b>d</b>) activity in fibroblasts (BJ). Data are mean ± SD (<span class="html-italic">n</span> = 3), * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span>&lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001 compared to the control (dashed line, 100% of enzyme activity) (Dunnett test).</p>
Full article ">
11 pages, 260 KiB  
Article
Replacement Therapy with Blood Products in People Living with HIV
by Mihaela Cristina Olariu, Mihaela Adela Iancu, Mihai Hristu Olariu, Victoria Aramă, Mădălina Simoiu, Miruna Maria Cruceru, Ecaterina Constanta Barbu, Paul Balanescu and Mihai Lazar
Trop. Med. Infect. Dis. 2024, 9(9), 213; https://doi.org/10.3390/tropicalmed9090213 - 13 Sep 2024
Viewed by 274
Abstract
Cytopenias or coagulation deficiencies can occur in people living with HIV (PLWH). The severity of these disorders is influenced by the low levels of CD4+ lymphocytes, viral load, and the stage of viral infection. The aim of our retrospective observational study was to [...] Read more.
Cytopenias or coagulation deficiencies can occur in people living with HIV (PLWH). The severity of these disorders is influenced by the low levels of CD4+ lymphocytes, viral load, and the stage of viral infection. The aim of our retrospective observational study was to determine the frequency of cytopenias and coagulation deficiencies in PLWH as well as the need for replacement therapy with blood products. We sought to determine whether there is an association between severe anemia or thrombocytopenia (requiring replacement therapy) and CD4+T lymphocyte levels. All 29 patients were critically ill, with 27 out of 29 (93%) in advanced stages of HIV disease and 23 out of 29 (79%) having CD4+ lymphocyte counts below 200 cells/microL. Most patients were either late presenters (45%) or had been lost to follow-up (41%). In addition to HIV infection, various conditions that could alter hematologic parameters were associated, including co-infections with hepatitis viruses, tuberculosis at various sites, malignant diseases, sepsis, SARS-CoV-2 infection, or other opportunistic infections. No significant correlation was found between severe anemia or severe thrombocytopenia or coagulation deficiencies and the CD4+T lymphocyte count. Our data suggest that these hematological disorders in patients with advanced HIV infection are more likely to be associated comorbidities rather than the HIV infection per se. Full article
(This article belongs to the Special Issue HIV Testing, Prevention and Care Interventions)
15 pages, 4584 KiB  
Article
Interactions of Saccharomyces cerevisiae and Lactiplantibacillus plantarum Isolated from Light-Flavor Jiupei at Various Fermentation Temperatures
by Pu Yang, Bo Xi, Ying Han, Jiayang Li, Lujun Luo, Chaofan Qu, Junfang Li, Shuai Liu, Le Kang, Baoqing Bai, Ben Zhang, Shaojie Zhao, Pan Zhen and Lizhen Zhang
Foods 2024, 13(18), 2884; https://doi.org/10.3390/foods13182884 - 12 Sep 2024
Viewed by 272
Abstract
Chinese Baijiu is a famous fermented alcoholic beverage in China. Interactions between key microorganisms, i.e., Saccharomyces cerevisiae and Lactiplantibacillus plantarum, have recently been reported at specific temperatures. However, empirical evidence of their interactions at various temperatures during fermentation is lacking. The results [...] Read more.
Chinese Baijiu is a famous fermented alcoholic beverage in China. Interactions between key microorganisms, i.e., Saccharomyces cerevisiae and Lactiplantibacillus plantarum, have recently been reported at specific temperatures. However, empirical evidence of their interactions at various temperatures during fermentation is lacking. The results of this study demonstrated that S. cerevisiae significantly suppressed the viability and lactic acid yield of L. plantarum when they were cocultured above 15 °C. On the other hand, L. plantarum had no pronounced effect on the growth and ethanol yield of S. cerevisiae in coculture systems. S. cerevisiae was the main reducing sugar consumer. Inhibition of lactic acid production was also observed when elevated cell density of L. plantarum was introduced into the coculture system. A proteomic analysis indicated that the enzymes involved in glycolysis, lactate dehydrogenase, and proteins related to phosphoribosyl diphosphate, ribosome, and aminoacyl-tRNA biosynthesis in L. plantarum were less abundant in the coculture system. Collectively, our data demonstrated the antagonistic effect of S. cerevisiae on L. plantarum and provided insights for effective process management in light-flavor Baijiu fermentation. Full article
(This article belongs to the Section Food Microbiology)
Show Figures

Figure 1

Figure 1
<p>Microbial biomass in monoculture and coculture systems at various temperatures: (<b>a</b>) 30 °C; (<b>b</b>) 27 °C; (<b>c</b>) 24 °C; (<b>d</b>) 21 °C; (<b>e</b>) 18 °C; (<b>f</b>) 15 °C; (<b>g</b>) 12 °C; and (<b>h</b>) 9 °C.</p>
Full article ">Figure 2
<p>pH changes in monoculture and coculture systems at various temperatures: (<b>a</b>) 30 °C; (<b>b</b>) 27 °C; (<b>c</b>) 24 °C; (<b>d</b>) 21 °C; (<b>e</b>) 18 °C; (<b>f</b>) 15 °C; (<b>g</b>) 12 °C; and (<b>h</b>) 9 °C.</p>
Full article ">Figure 3
<p>Lactic acid yield of <span class="html-italic">Lactiplantibacillus plantarum</span> R2 in monoculture and coculture systems at various temperatures: (<b>a</b>) 30 °C; (<b>b</b>) 27 °C; (<b>c</b>) 24 °C; (<b>d</b>) 21 °C; (<b>e</b>) 18 °C; (<b>f</b>) 15 °C; (<b>g</b>) 12 °C; and (<b>h</b>) 9 °C.</p>
Full article ">Figure 4
<p>Ethanol production by <span class="html-italic">Saccharomyces cerevisiae</span> Y28 in monoculture and coculture systems at various temperatures: (<b>a</b>) 30 °C; (<b>b</b>) 27 °C; (<b>c</b>) 24 °C; (d) 21 °C; (<b>e</b>) 18 °C; (<b>f</b>) 15 °C; (<b>g</b>) 12 °C; and (<b>h</b>) 9 °C.</p>
Full article ">Figure 5
<p>Utilization of reducing sugars in monoculture and coculture systems at various temperatures: (<b>a</b>) 30 °C; (<b>b</b>) 27 °C; (<b>c</b>) 24 °C; (<b>d</b>) 21 °C; (<b>e</b>) 18 °C; (<b>f</b>) 15 °C; (<b>g</b>) 12 °C; and (<b>h</b>) 9 °C.</p>
Full article ">Figure 6
<p>Microbial biomass (<b>a</b>–<b>c</b>), pH changes (<b>d</b>–<b>f</b>), lactic acid yield (<b>g</b>–<b>i</b>), ethanol yield (<b>j</b>–<b>l</b>), and utilization of reducing sugars (<b>m</b>–<b>o</b>) in monoculture and coculture systems under 30 °C (<b>a</b>,<b>d</b>,<b>g</b>,<b>j</b>,<b>m</b>), 21 °C (<b>b</b>,<b>e</b>,<b>h</b>,<b>k</b>,<b>n</b>), and 15 °C (<b>c</b>,<b>f</b>,<b>i</b>,<b>l</b>,<b>o</b>).</p>
Full article ">Figure 7
<p>General features of the proteomic pattern of <span class="html-italic">L. plantarum</span>. (<b>a</b>) PCA analysis of the protein expression patterns of <span class="html-italic">L. plantarum</span> in the presence or absence of <span class="html-italic">S. cerevisiae</span>. (<b>b</b>) Number of differentially expressed proteins. (<b>c</b>) Venn map of the downregulated proteins in the coculture system between 14 h and 16 h. (<b>d</b>) KEGG pathways of the downregulated proteins in the coculture system shared at 14 h and 16 h. Co14, sampled at 14 h in the coculture system; Co16, sampled at 16 h in the coculture system; Mo14, sampled at 16 h in the monoculture system; and Mo16, sampled at 16 h in the monoculture system.</p>
Full article ">Figure 8
<p>Changes in expression levels of proteins associated with lactic acid fermentation and phosphoribosyl diphosphate biosynthesis pathways.</p>
Full article ">
15 pages, 4166 KiB  
Article
Risk Assessment of Fenpropathrin: Cause Hepatotoxicity and Nephrotoxicity in Common Carp (Cyprinus carpio L.)
by Gongming Zhu, Zhihui Liu, Hao Wang, Shaoyu Mou, Yuanyuan Li, Junguo Ma and Xiaoyu Li
Int. J. Mol. Sci. 2024, 25(18), 9822; https://doi.org/10.3390/ijms25189822 - 11 Sep 2024
Viewed by 234
Abstract
The synthetic pyrethroid pesticide fenpropathrin (FEN) is extensively used worldwide and has frequently been detected in biota and the environment, whilst the negative effects and toxicological mechanisms of FEN on non-target organisms are still unknown. In the present study, healthy immature common carp [...] Read more.
The synthetic pyrethroid pesticide fenpropathrin (FEN) is extensively used worldwide and has frequently been detected in biota and the environment, whilst the negative effects and toxicological mechanisms of FEN on non-target organisms are still unknown. In the present study, healthy immature common carp were treated with FEN (0.45 and 1.35 μg/L) for a duration of 14 days, and the negative impacts and possible mechanisms of FEN on fish were investigated. Biochemical analyses results showed that FEN exposure altered the levels of glucose (GLU), total cholesterol (T-CHO), triglyceride (TG), albumin (ALB), alkaline phosphatase (ALP), alanine transaminase (ALT), and aspartate transaminase (AST) in carp serum, and caused histological injury of the liver and kidney, indicating that FEN may cause hepatotoxicity and nephrotoxicity in carp. In addition, FEN also altered the activities of superoxide dismutase (SOD) and catalase (CAT) in carp serum, upregulated the levels of reactive oxygen species (ROS), and elevated the levels of malondialdehyde (MDA) in the liver and kidney. Meanwhile, tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) levels were also upregulated, indicating that oxidative stress and inflammatory reaction may be involved in the hepatotoxicity and nephrotoxicity caused by FEN. Furthermore, RNA-seq analysis results revealed that FEN treatment induced a diverse array of transcriptional changes in the liver and kidney and downregulated differentially expressed genes (DEGs) were concentrated in multiple pathways, especially cell cycle and DNA replication, suggesting that FEN may induce cell cycle arrest of hepatocytes and renal cells, subsequently inducing hepatotoxicity and nephrotoxicity. Overall, the present study enhances our comprehension of the toxic effects of FEN and provides empirical evidence to support the risk assessment of FEN for non-target organisms. Full article
(This article belongs to the Section Molecular Toxicology)
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>Changes of the serum biochemical indicators in common carp after a 14 d exposure to FEN. Values are presented as the mean ± SD. * <span class="html-italic">p</span> &lt; 0.05 and ** <span class="html-italic">p</span> &lt; 0.01 compared to the control.</p>
Full article ">Figure 2
<p>Histopathological analysis of the carp liver and kidney after FEN treatment. Representative H&amp;E-stained liver graphs from controls (<b>A</b>), 0.45 μg/L (<b>B</b>), and 1.35 μg/L groups (<b>C</b>). Representative kidney images from control (<b>D</b>), 0.45 μg/L (<b>E</b>), and 1.35 μg/L groups (<b>F</b>). AM: aggregated melanomacrophages; EBS: expansion of Bowman’s space; ECL: eosinophilic cytoplasm loss; HSC: hepatic sinusoidal congestion; HSD: hepatic sinusoidal dilatation; ICI: inflammatory cell infiltration; RTB: renal tubules blocked; RTIC: renal tubules intratubular congestion. Black arrows indicate the site of tissue injury. (Scale: 100 μm; 50 μm).</p>
Full article ">Figure 3
<p>Changes of oxidative stress-related indicators in the carp liver and kidney after a 14 d exposure to FEN. Values are presented as the mean ± SD. * <span class="html-italic">p</span> &lt; 0.05 and ** <span class="html-italic">p</span> &lt; 0.01 compared to the controls. d represents the term day. (<b>A</b>) ROS levels in the carp liver. (<b>B</b>) MDA contents in the carp liver. (<b>C</b>) ROS levels in the carp kidney. (<b>D</b>) MDA contents in the carp kidney.</p>
Full article ">Figure 4
<p>Changes of inflammation-related indicators in the carp liver and kidney after a 14 d exposure to FEN. Values are presented as the mean ± SD. The presence of asterisks indicates significant differences as compared to the control groups (* <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01). d represents the term day. (<b>A</b>) The levels of TNF-α in the liver. (<b>B</b>) IL-1β contents in the liver. (<b>C</b>) TNF-α levels in the kidney. (<b>D</b>) IL-1β contents in the kidney.</p>
Full article ">Figure 5
<p>Transcriptional changes in the liver and kidney of common carp after a 14 d exposure to FEN. Gene expression detection in the carp liver (<b>A</b>) and kidney (<b>B</b>) after FEN treatment using qPCR. Correlative analyses of qPCR and RNA-seq analysis results in the carp liver (<b>C</b>) and kidney (<b>D</b>). KEGG pathways of DEGs in the liver (<b>E</b>) and kidney (<b>F</b>) in both FEN-treated groups. Graph of significant gene networks associated with DNA replication and cell cycle in the carp liver (<b>G</b>) and kidney (<b>H</b>). * <span class="html-italic">p</span> &lt; 0.05 and ** <span class="html-italic">p</span> &lt; 0.01 compared to the controls.</p>
Full article ">Figure 5 Cont.
<p>Transcriptional changes in the liver and kidney of common carp after a 14 d exposure to FEN. Gene expression detection in the carp liver (<b>A</b>) and kidney (<b>B</b>) after FEN treatment using qPCR. Correlative analyses of qPCR and RNA-seq analysis results in the carp liver (<b>C</b>) and kidney (<b>D</b>). KEGG pathways of DEGs in the liver (<b>E</b>) and kidney (<b>F</b>) in both FEN-treated groups. Graph of significant gene networks associated with DNA replication and cell cycle in the carp liver (<b>G</b>) and kidney (<b>H</b>). * <span class="html-italic">p</span> &lt; 0.05 and ** <span class="html-italic">p</span> &lt; 0.01 compared to the controls.</p>
Full article ">Figure 6
<p>A summary of hepatotoxicity and nephrotoxicity of FEN in common carp. Arrows indicate up-regulation (↑) or down-regulation (↓) of expression.</p>
Full article ">
16 pages, 2267 KiB  
Article
New Advances in the Study of CMTM6, a Focus on Its Novel Non-Canonical Cellular Locations, and Functions beyond Its Role as a PD-L1 Stabilizer
by Pedro Ivan Urciaga-Gutierrez, Ramon Antonio Franco-Topete, Blanca Estela Bastidas-Ramirez, Fabiola Solorzano-Ibarra, Jose Manuel Rojas-Diaz, Nadia Tatiana Garcia-Barrientos, Ksenia Klimov-Kravtchenko, Martha Cecilia Tellez-Bañuelos, Pablo Cesar Ortiz-Lazareno, Oscar Peralta-Zaragoza, Angelica Meneses-Acosta, Alan Guillermo Alejandre-Gonzalez, Miriam Ruth Bueno-Topete, Jesse Haramati and Susana del Toro-Arreola
Cancers 2024, 16(18), 3126; https://doi.org/10.3390/cancers16183126 - 11 Sep 2024
Viewed by 335
Abstract
CMTM6 is a membrane protein that acts as a regulator of PD-L1, maintaining its expression on the cell surface, and can prevent its lysosome-mediated degradation. It is unknown if CMTM6 is present in the plasma of patients with cervical cancer, and if it [...] Read more.
CMTM6 is a membrane protein that acts as a regulator of PD-L1, maintaining its expression on the cell surface, and can prevent its lysosome-mediated degradation. It is unknown if CMTM6 is present in the plasma of patients with cervical cancer, and if it has non-canonical subcellular localizations in cell lines derived from cervical cancer. Our objective was to determine whether CMTM6 is found in plasma derived from cervical cancer patients and its subcellular localization in cell lines. Patient plasma was separated into exosome-enriched, exosome-free, and total plasma fractions. The levels of CMTM6 in each fraction were determined using ELISA and Western blot. Finally, for the cellular model, HeLa, SiHa, CaSki, and HaCaT were used; the subcellular locations of CMTM6 were determined using immunofluorescence and flow cytometry. Soluble CMTM6 was found to be elevated in plasma from patients with cervical cancer, with a nearly three-fold increase in patients (966.27 pg/mL in patients vs. 363.54 pg/mL in controls). CMTM6 was preferentially, but not exclusively, found in the exosome-enriched plasma fraction, and was positively correlated with exosomal PD-L1; CMTM6 was identified in the membrane, intracellular compartments, and culture supernatant of the cell lines. These results highlight that CMTM6, in its various presentations, may play an important role in the biology of tumor cells and in immune system evasion. Full article
(This article belongs to the Special Issue Extracellular Vesicles (EVs) in Cancer Diagnostics and Therapy)
Show Figures

Figure 1

Figure 1
<p>Total CMTM6 and total PD-L1 in plasma from the healthy donors (HDs) group and the cervical cancer patients (CC) group. (<b>a</b>) Concentrations of CMTM6 in the plasma of HDs (<span class="html-italic">n</span> = 23) and CC (<span class="html-italic">n</span> = 23) were measured by enzyme-linked immunosorbent assay (ELISA). Data are shown as pg/mL of CMTM6. (<b>b</b>) PD-L1 levels in the plasma of HDs (<span class="html-italic">n</span> = 11) and CC (<span class="html-italic">n</span> = 21) are shown as pg/mL of PD-L1. Student’s <span class="html-italic">t</span>-test was used. * <span class="html-italic">p</span> ≤ 0.05, ** <span class="html-italic">p</span> ≤ 0.01.</p>
Full article ">Figure 2
<p>CMTM6 and PD-L1 were found in exosomes from the plasma of the healthy donor group (HD) and the group of patients with cervical cancer (CC). (<b>a</b>) CMTM6 is preferentially released in exosomes in both the HD (<span class="html-italic">n</span> = 10) and CC (<span class="html-italic">n</span> = 20) groups; data shown as pg/mL of CMTM6. (<b>b</b>) PD-L1 was elevated in the exosome-enriched plasma fractions from both the HDs (<span class="html-italic">n</span> = 6) and CC (<span class="html-italic">n</span> = 15); data shown as pg/mL. (<b>c</b>) Correlation between exosomal CMTM6 and PD-L1 in HD samples (<span class="html-italic">r</span> = 0.996). (<b>d</b>) Correlation between exosomal CMTM6 and PD-L1 in CC samples (<span class="html-italic">r</span> = 0.8346). (<b>e</b>) CMTM6 was found to increase in the exosomal fractions from HDs and CC patients by Western blot. CD63 was used as an exosomal marker. The uncropped blots are shown in <a href="#app1-cancers-16-03126" class="html-app">Figure S1</a>. Wilcoxon ranked test was used. * <span class="html-italic">p</span> ≤ 0.05, ** <span class="html-italic">p</span> ≤ 0.01, *** <span class="html-italic">p</span> &lt; 0.005.</p>
Full article ">Figure 2 Cont.
<p>CMTM6 and PD-L1 were found in exosomes from the plasma of the healthy donor group (HD) and the group of patients with cervical cancer (CC). (<b>a</b>) CMTM6 is preferentially released in exosomes in both the HD (<span class="html-italic">n</span> = 10) and CC (<span class="html-italic">n</span> = 20) groups; data shown as pg/mL of CMTM6. (<b>b</b>) PD-L1 was elevated in the exosome-enriched plasma fractions from both the HDs (<span class="html-italic">n</span> = 6) and CC (<span class="html-italic">n</span> = 15); data shown as pg/mL. (<b>c</b>) Correlation between exosomal CMTM6 and PD-L1 in HD samples (<span class="html-italic">r</span> = 0.996). (<b>d</b>) Correlation between exosomal CMTM6 and PD-L1 in CC samples (<span class="html-italic">r</span> = 0.8346). (<b>e</b>) CMTM6 was found to increase in the exosomal fractions from HDs and CC patients by Western blot. CD63 was used as an exosomal marker. The uncropped blots are shown in <a href="#app1-cancers-16-03126" class="html-app">Figure S1</a>. Wilcoxon ranked test was used. * <span class="html-italic">p</span> ≤ 0.05, ** <span class="html-italic">p</span> ≤ 0.01, *** <span class="html-italic">p</span> &lt; 0.005.</p>
Full article ">Figure 3
<p>CMTM6 and PD-L1 were found in the lysates of CC-derived cells. (<b>a</b>) CMTM6 expression was found to be higher in the total lysate of CaSki cells compared to those of HeLa and SiHa cells, shown as bands corresponding to the approximate molecular weight reported for CMTM6 and its densitometric analysis. (<b>b</b>) The bands corresponding to the molecular weight reported for PD-L1 were also found in the three cell lines, coinciding again to show that CaSki cells express the highest levels of this protein; the band pattern and its densitometric analysis are shown. In both cases, β-actin was used as a constitutive protein and loading control. The uncropped blots are shown in <a href="#app1-cancers-16-03126" class="html-app">Figure S2</a>. Data are shown as mean ± SD; three independent experiments were performed for each condition. * <span class="html-italic">p</span> ≤ 0.05, ** <span class="html-italic">p</span> ≤ 0.01, *** <span class="html-italic">p</span> ≤ 0.001, **** <span class="html-italic">p</span> ≤ 0.0001, ns: no significance.</p>
Full article ">Figure 4
<p>CMTM6 was found in the cell membrane and intracellularly in cell lines derived from cervical cancer. (<b>a</b>) The percentage of CMTM6-positive cells was determined by flow cytometry. CMTM6 was found both intracellularly and associated with the plasma membranes of all cell lines. Interestingly, the highest percentages of CMTM6, both intracellular and on the membrane, were found in CaSki cells. Data are shown as mean ± SD; three independent experiments were performed for each condition. * <span class="html-italic">p</span> ≤ 0.05, ** <span class="html-italic">p</span> ≤ 0.01, *** <span class="html-italic">p</span> ≤ 0.001, **** <span class="html-italic">p</span> ≤ 0.0001, ns: no significance. (<b>b</b>) Immunofluorescence staining verified that CMTM6 (AF-594, red stain) is found in different subcellular locations such as intracellular (cytoplasm shown with diamond-tipped arrow) and the plasma membrane (closed arrow). The nuclei (open arrow) are stained with DAPI (blue). Note the intracellular staining in SiHa cells, which obscures the nucleus, and the visible nucleus and membrane staining in CaSki cells. Images taken using the 10× objective (left side) and 30× (right side).</p>
Full article ">Figure 5
<p>PD-L1 is present in the cell membranes and cytoplasm of cell lines derived from cervical cancer. (<b>a</b>) The percentages of PD-L1-positive cells were determined by traditional flow cytometry. Interestingly, the highest percentages of membrane PD-L1 were in CaSki cells. Data are shown as mean ± SD; two independent experiments were performed for each condition. * <span class="html-italic">p</span> ≤ 0.05, ** <span class="html-italic">p</span> ≤ 0.01, **** <span class="html-italic">p</span> ≤ 0.0001, ns: no significance. (<b>b</b>) Immunofluorescence was used to verify if PD-L1 (AF-488, green stain) was found in different subcellular locations, such as intracellular (cytoplasm marked with diamond-tipped arrow) and plasma membrane (closed arrow). Nuclei were stained with DAPI (blue). Images taken using the 10× objective (left side) and 30× (right side).</p>
Full article ">Figure 6
<p>CMTM6 released by cell lines derived from cervical cancer. ELISA of culture supernatants to quantify the total levels of supernatant CMTM6. Detectable levels of supernatant CMTM6 were seen in all cell lines; however, HeLa cells were found to release the highest concentration (11,015 pg/mL). Data are shown as mean ± SD; two independent experiments were performed for each condition. * <span class="html-italic">p</span> &lt; 0.05; *** <span class="html-italic">p</span> &lt; 0.001; **** <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">
10 pages, 890 KiB  
Article
Changes in the HIV Epidemic in Lower Silesia, Poland, Between 2010 and 2020: The Characteristics of the Key Populations
by Aleksandra Kozieł, Aleksandra Cieślik, Łucja Janek, Aleksandra Szymczak, Igor Domański, Brygida Knysz and Bartosz Szetela
Viruses 2024, 16(9), 1445; https://doi.org/10.3390/v16091445 - 11 Sep 2024
Viewed by 310
Abstract
The HIV (Human Immunodeficiency Virus) epidemic remains a significant public health issue, requiring ongoing access to preventive methods. This study aimed to analyze the evolution of the HIV epidemic in Lower Silesia from 2010 to 2020, focusing on the key populations. A retrospective [...] Read more.
The HIV (Human Immunodeficiency Virus) epidemic remains a significant public health issue, requiring ongoing access to preventive methods. This study aimed to analyze the evolution of the HIV epidemic in Lower Silesia from 2010 to 2020, focusing on the key populations. A retrospective analysis of the medical records from newly diagnosed HIV patients at a major HIV clinic in Wroclaw was conducted, examining demographic data, infection routes, and laboratory results. An 84% increase in newly diagnosed HIV cases was observed over the decade, with the most common route of infection being sex between men (70% among those with a known infection route). These patients were generally in better clinical condition compared to their heterosexual counterparts, as indicated by a higher median CD4+ T cell count (465/μL vs. 250/μL). The changes in clinical status and infection routes were statistically significant. The HIV epidemic in Lower Silesia has shifted, with a notable rise in new infections among men who have sex with men. Heterosexual patients were often diagnosed at more advanced stages. Prevention strategies should adapt to these changing trends, with education and testing accessibility remaining priorities nationwide. Full article
(This article belongs to the Section Human Virology and Viral Diseases)
Show Figures

Figure 1

Figure 1
<p>CD4+ T cell count depending on the route of infection in 2010, 2016, and 2020. Outliers—all values less than <span class="html-italic">Q1</span> + 1.5 × <span class="html-italic">IQR</span> and greater than that, up to <span class="html-italic">Q3</span> + 1.5 × <span class="html-italic">IQR</span>.</p>
Full article ">Figure 2
<p>Presence of anti-HCV antibodies dependent on the year of study.</p>
Full article ">
19 pages, 4491 KiB  
Article
Myrtus communis L. Essential Oil Exhibits Antiviral Activity against Coronaviruses
by Dar-Yin Li, Matthew G. Donadu, Taylor Shue, Georgios Dangas, Antonis Athanasiadis, Shuiyun Lan, Xin Wen, Basem Battah, Stefania Zanetti, Vittorio Mazzarello, Stefan G. Sarafianos, Marco Ferrari and Eleftherios Michailidis
Pharmaceuticals 2024, 17(9), 1189; https://doi.org/10.3390/ph17091189 - 10 Sep 2024
Viewed by 412
Abstract
Human coronaviruses are a continuous threat to the human population and have limited antiviral treatments, and the recent COVID-19 pandemic sparked interest in finding new antiviral strategies, such as natural products, to combat emerging coronaviruses. Rapid efforts in the scientific community to identify [...] Read more.
Human coronaviruses are a continuous threat to the human population and have limited antiviral treatments, and the recent COVID-19 pandemic sparked interest in finding new antiviral strategies, such as natural products, to combat emerging coronaviruses. Rapid efforts in the scientific community to identify effective antiviral agents for coronaviruses remain a focus to minimize mortalities and global setbacks. In this study, an essential oil derived from Myrtus communis L. (MEO) is effective against HCoV-229E and HCoV-OC43 virus infections in comparison to two FDA-approved drugs, Remdesivir and Nirmatrelvir. Gas-chromatography and mass spectrometry were used to identify the chemical composition of MEO. Slight antioxidant activity was observed in MEO, indicating a role in oxidative stress. A dose–response curve measuring the EC50 indicates a high potency against HCoV-229E and HCoV-OC43 virus infections on Huh7.5 cells with low cytotoxicity using a PrestoBlue cell viability assay. Our findings demonstrate that MEO exhibits potent antiviral activity against HCoV-229E and HCoV-OC43 on Huh7.5 cells within a low-cytotoxicity range, but not on SARS-CoV-2. Artificial bacterial chromosome plasmids that expressed SARS-CoV-2 used for replicon—to determine viral replication and viral assembly/egress on HEK293T/17 cells—and virus-like particles on Huh7.5-AT cells—to determine viral entry and assembly/egress—showed no antiviral activity with MEO in comparison to Remdesivir. This study reveals the potential effectiveness of MEO as an alternative natural remedy to treat human coronaviruses and a potential antiviral agent for future coronavirus infections. Full article
Show Figures

Figure 1

Figure 1
<p>MEO inhibits HCoV-229E infection. (<b>A</b>) Experimental design of MEO experiment for dose–response curve. Huh7.5 cells were seeded in two 96-well plates with Remdesivir and Nirmatrelvir as antiviral controls. The experiment was performed in triplicate, and the starting concentration for MEO was 1:1000 (0.8469 mg/mL) and received a 1:2 serial dilution. The starting concentrations for Remdesivir and Nirmatrelvir were 250 nM and 25 µM, respectively, and were diluted with a 1:2 serial dilution. After HCoV-229E was added to the plates an hour after drug treatment, cells were fixed with 4% PFA one day post-infection. Immunofluorescent staining (IF) was performed to visualize infected cells using Cytation 7. (<b>B</b>) Dose–response curve showing that MEO has antiviral activity against HCoV-229E with EC<sub>50</sub> = 0.1204 mg/mL MEO concentration starting at 1:1000 (0.8469 mg/mL) with a 1:2 serial dilution and infected with 1:10 HCoV-229E virus. (<b>C</b>) Cytotoxicity assay measuring cell viability in MEO-treated Huh7.5 cells. A 1:10 (84.69 mg/mL) starting concentration for MEO was used with a 1:2 serial dilution. Huh7.5 cells treated with MEO were normalized to the untreated Huh7.5 cells.</p>
Full article ">Figure 2
<p>Immunofluorescent staining for HCoV-229E Spike protein. Huh7.5 cells without MEO treatment showed a mean fluorescence intensity of 22 with HCoV-229E. At a 1:2000 (0.42345 mg/mL) Myrtus concentration, the HCoV-229E viral infection has a mean fluorescence intensity of 7. Nuclei were stained with Hoechst, and HCoV-229E was stained with HCoV-229E spike protein and Alexa Fluor 488, labeled goat anti-mouse secondary antibody, and was imaged at a 1000 µm scale.</p>
Full article ">Figure 3
<p>MEO inhibits HCoV-OC43 infection. (<b>A</b>) Experimental layout of MEO with HCoV-OC43 infection to determine EC<sub>50</sub>. Two collagen-coated 96-wells plates were seeded with Huh7.5 cells to evaluate the dose–response curve of Remdesivir, Nirmatrelvir, and MEO. Each drug was conducted in triplicates with the starting concentration for MEO to be 1:1000 (0.8469 mg/mL) and serially diluted 1:2. The starting concentrations for Remdesivir and Nirmatrelvir were 7 µM and 25 µM, respectively, and were diluted with a 1:2 serial dilution. An hour after drug treatment, HCoV-OC43 was added, and cells were fixed with 4% PFA at 3 days post-infection. Immunofluorescent staining (IF) was performed to visualize infected cells using the Cytation 7. (<b>B</b>) A dose–response curve showed that MEO has antiviral activity against HCoV-OC43 with EC<sub>50</sub> = 1.405 mg/mL MEO concentration starting at a concentration of 1:1000 (0.8469 mg/mL) with a 1:2 serial dilution and infected with 1:20 HCoV-OC43E virus.</p>
Full article ">Figure 4
<p>Immunofluorescent staining for HCoV-OC43 spike protein. Huh7.5 cells without MEO treatment showed a mean fluorescence intensity of 12 with HCoV-OC43. At a 1:1000 (0.8469 mg/mL) MEO concentration, HCoV-OC43 viral infection has a mean fluorescence intensity of 4. Nuclei were stained with Hoechst and HCoV-OC43 was stained with anti-coronavirus antibody, OC-43 strain, clone 541-8F, and Alexa Fluor 488, labeled goat anti-mouse secondary antibody, and was imaged at a 1000 µm scale.</p>
Full article ">Figure 5
<p>MEO does not inhibit SARS-CoV-2 viral replication based on SARS-CoV-2 replicon. (<b>A</b>) Normalized SARS-CoV-2 replicon transfection to determine if MEO inhibits viral replication. Using GFP reporter in the SARS-CoV-2 replicon to calculate the percent of transfected cells, there was no difference in the number of transfected cells compared to normalized and untreated wells. NLuc activity from the SARS-CoV-2 replicon plasmid was used to quantify the amount of viral replication under MEO-treated conditions. Titration of MEO with SARS-CoV-2 replicon transfected cells showed no difference in viral replication via NLuc activity. Cell viability is not affected by SARS-CoV-2 replicon, nor by MEO cytotoxicity at the tested MEO concentrations. The relative luminescence graph validates that viral replicon is not inhibited by MEO. (<b>B</b>) Remdesivir substantially inhibited SARS-CoV-2 viral replication and normalized transfection level similar to the relative luminescence units, as untreated wells received about an eight-fold increase compared to 7.5 µM. At 15 µM of Remdesivir, cell viability dropped below 50%, exhibiting Remdesivir cytotoxicity.</p>
Full article ">Figure 6
<p>No inhibition against SARS-CoV-2 VLPs for MEO. (<b>A</b>) Immunofluorescence images showed no difference in VLP inhibition for untreated and MEO-treated wells at 1:200 (4.2345 mg/mL) concentration. Remdesivir inhibited SARS-CoV-2 VLP in a dose-dependent manner, which acted as positive control. To determine the percentage of cells infected with SARS-CoV-2 VLPs, the cells were counterstained with Hoechst and imaged for GFP reporter signal from the replicon plasmids and Hoechst dye using Cytation 7. All images are in 1000 µm scale. (<b>B</b>) The VLP transduction assay with MEO treatment showed similar infection levels as untreated wells. At 1:100 (8.469 mg/mL) concentration of MEO, cells were not viable, and viral replication remained consistent. (<b>C</b>) Remdesivir showed potent inhibition against SARS-CoV-2 VLP as an inhibitor of SARS-CoV-2 viral replication.</p>
Full article ">Figure 7
<p>MEO treatment has little impact SARS-CoV-2 Omicron BA.1 VLP formation/release. SARS-CoV-2 BA.1 VLPs were produced in HEK293T/17 cells that were pre-treated with either a 1:1000 (0.8469 mg/mL) or 1:500 (1.6938 mg/mL) concentration of MEO in DMEM (10% FBS + 1% NEAA) to assess the effect of MEO on the formation of infectious VLPs. VLPs were harvested via centrifugation and concentrated 20× using 100,000 MW Amicon filter units. VLPs were titrated on Huh7.5-AT cells at a starting dilution of 1:5 and continued with a 1:2 dilution. At one day post-transduction, the cells were counterstained with 1:5000 Hoechst dye and imaged using Cytation 7 for the number of GFP+ and total cells. Then, the cell culture supernatant was measured for NLuc activity. (<b>A</b>) Hoechst staining shows that there was a slight decrease in cell viability for VLPs formed in the presence of MEO treatment in a dose-dependent manner (<span class="html-italic">p</span> &lt; 0.0001). (<b>B</b>) Analysis of the GFP+ cells representing cells successfully transduced with VLP and undergoing replication of the replicon plasmid showed minor differences between MEO-treated and untreated VLPs, but only at the highest dilutions of VLP delivery (<span class="html-italic">p</span> = 0.01). (<b>C</b>) NLuc activity shows no difference between MEO VLPs and untreated VLPs. Overall, MEO treatment during VLP production has no effect on nascent VLP particles.</p>
Full article ">
17 pages, 1353 KiB  
Case Report
Identification of SYNJ1 in a Complex Case of Juvenile Parkinsonism Using a Multiomics Approach
by Ester Leno-Durán, Luisa Arrabal, Susana Roldán, Inmaculada Medina, Clara Alcántara-Domínguez, Victor García-Cabrera, Jorge Saiz, Coral Barbas, Maria José Sánchez, Carmen Entrala-Bernal, Francisco Fernández-Rosado, Jose Antonio Lorente, Purificacion Gutierrez-Ríos and Luis Javier Martínez-Gonzalez
Int. J. Mol. Sci. 2024, 25(17), 9754; https://doi.org/10.3390/ijms25179754 - 9 Sep 2024
Viewed by 330
Abstract
This study aimed to elucidate the genetic causes underlying the juvenile parkinsonism (JP) diagnosed in a girl with several family members diagnosed with spinocerebellar ataxia type 2 (SCA2). To achieve this, whole-exome sequencing, analysis of CAG repeats, RNA sequencing analysis on fibroblasts, and [...] Read more.
This study aimed to elucidate the genetic causes underlying the juvenile parkinsonism (JP) diagnosed in a girl with several family members diagnosed with spinocerebellar ataxia type 2 (SCA2). To achieve this, whole-exome sequencing, analysis of CAG repeats, RNA sequencing analysis on fibroblasts, and metabolite identification were performed. As a result, a homozygous missense mutation SNP T>C (rs2254562) in synaptojamin 1 (SYNJ1), which has been implicated in the regulation of membrane trafficking in the synaptic vesicles, was identified. Additionally, we observed overexpression of L1 cell adhesion molecule (L1CAM), Cdc37, GPX1, and GPX4 and lower expression of ceruloplasmin in the patient compared to the control. We also found changes in sphingolipid, inositol, and inositol phosphate metabolism. These findings help to clarify the mechanisms of JP and suggest that the etiology of JP in the patient may be multifactorial. This is the first report of the rs2254562 mutation in the SYNJ gene identified in a JP patient with seizures and cognitive impairment. Full article
(This article belongs to the Special Issue Molecular Research on Neurodegenerative Diseases 4.0)
Show Figures

Figure 1

Figure 1
<p>I-123-Ioflupane SPECT image of the brain patient. (<b>A</b>) Healthy control showing both striata with a normal comma shape and sharp borders, presenting low background activity. (<b>B</b>) The patient presented asymmetric striata, with a lower size in the left striata, an oval appearance, and increased background activity.</p>
Full article ">Figure 2
<p>Metabolite set enrichment analysis perform by MetaboAnalyst.</p>
Full article ">
23 pages, 42125 KiB  
Article
Integration of Transcriptomics and Metabolomics Reveals the Antitumor Mechanism of Protopanaxadiol Triphenylphosphate Derivative in Non-Small-Cell Lung Cancer
by Liu Han, Xingbo Bian, Xiangyu Ma, Ting Ren, Yawei Li, Lijing Huang, Zebo Tang, Liancong Gao, Sheng Chang and Xin Sun
Molecules 2024, 29(17), 4275; https://doi.org/10.3390/molecules29174275 - 9 Sep 2024
Viewed by 412
Abstract
The objective of this study was to enhance the membrane permeability and anticancer effectiveness of (20S)-protopanaxadiol (PPD) by introducing triphenylphosphonium into the OH group at the C-3 site. This study shows that the anti-proliferation activity of CTPPPPD, with an IC50 value [...] Read more.
The objective of this study was to enhance the membrane permeability and anticancer effectiveness of (20S)-protopanaxadiol (PPD) by introducing triphenylphosphonium into the OH group at the C-3 site. This study shows that the anti-proliferation activity of CTPPPPD, with an IC50 value of 1.65 ± 0.10 μmol/L, was 33-times better than that of PPD (with an IC50 value of 54.56 ± 4.56 μmol/L) and superior to that of cisplatin (with an IC50 value of 1.82 ± 0.25 μmol/L) against A549 cells. Biological examinations suggested that CTPPPPD treatment reduced the growth rate of A549 cells, increased the permeability of cell membranes, and changed the structure of chromosomal DNA in a concentration-dependent manner. Annexin V/PI assay and flow cytometry were employed to detect the effect of CTPPPPD on the apoptosis of A549 cells. The results showed that CTPPPPD could induce the apoptosis of A549 cells, and the apoptosis rate of A549 cells treated with 0, 1.0, 2.0, and 4.0 μM of CTPPPPD for 24 h was 0%, 4.9%, 12.7%, and 31.0%, respectively. The integration of transcriptomics and metabolomics provided a systematic and detailed perspective on the induced antitumor mechanisms. A combined analysis of DEGs and DAMs suggested that they were primarily involved in the central carbon metabolism pathway in cancer, as well as the metabolism of aminoacyl-tRNA biosynthesis, alanine, aspartate, and glutamate. Central carbon metabolism in cancer-related genes, i.e., SLC16A3, FGFR3, LDHA, PGAM1, and SLC2A1, significantly reduced after treatment with CTPPPPD. In particular, the dominant mechanism responsible for total antitumor activity may be attributed to perturbations in the PI3K-AKT, MAPK, and P53 pathways. The findings derived from transcriptomics and metabolomics were empirically confirmed through q-PCR and molecular docking. Further analyses revealed that CTPPPPD could be a promising lead for the development of protopanaxadiol for non-small-cell lung cancer (NSCLC) drugs. Full article
(This article belongs to the Special Issue Anticancer Drug Discovery and Development II)
Show Figures

Figure 1

Figure 1
<p>Synthesis pathway of CTPPPPD.</p>
Full article ">Figure 2
<p>The effect of CTPPPPD on A549 cells. (<b>A</b>) Effects of CTPPPPD, PPD and Cisplatin on A549 cell proliferation. (<b>B</b>) Effects of CTPPPPD on A549 cell morphology observed under normal conditions. (<b>C</b>) Effects of CTPPPPD on A549 cell morphology observed by Hoechst 33,258 staining. (<b>D</b>) CTPPPPD induces A549 cell apoptosis. (<b>E</b>) Effects of CTPPPPD on A549 cell mitochondrial membrane potential detected by JC-1. *, **, *** and **** represent significant <span class="html-italic">p</span>-values ≤ 0.05, 0.01, 0.001, 0.0001, respectively.</p>
Full article ">Figure 3
<p>The screening results of DEGs from the model and CTPPPPD groups in A549 cell samples. (<b>A</b>) The volcanic plot of differential genes between the CTPPPPD and control groups. (<b>B</b>) Clustering heat map of differential genes between the CTPPPPD and control groups. (<b>C</b>) GO annotation analysis of CTPPPPD vs. control. (<b>D</b>) KEGG enrichment analysis of CTPPPPD vs. control.</p>
Full article ">Figure 4
<p>Overall analysis of DAMs. (<b>A</b>) Metabolite HMBD compound classification diagram. (<b>B</b>) PCA score plot of samples in cationic mode. (<b>C</b>) PCA score plot of samples in anionic mode. (<b>D</b>) OPLS-DA score plot of CTPPPPD vs. control in cationic mode. (<b>E</b>) OPLS-DA score plot of CTPPPPD vs. control in anionic mode.</p>
Full article ">Figure 5
<p>Overall analysis of DAMs. (<b>A</b>) The volcanic plot of DAMs between CTPPPPD and control groups in cationic mode. (<b>B</b>) The volcanic plot of DAMs between CTPPPPD and control groups in anionic mode. (<b>C</b>) Clustering heat map of the top 100 metabolites in CTPPPPD vs. control. (<b>D</b>) KEGG topology analysis of CTPPPPD vs. control.</p>
Full article ">Figure 6
<p>Integrated transcriptome and metabolome analysis in iPath 3.0. Red represents pathways annotated by the metabolic set and green represents pathways annotated by the gene set.</p>
Full article ">Figure 7
<p>Effect of CTPPPPD on NSCLC response.</p>
Full article ">Figure 8
<p>Integrated analysis of transcriptome and metabolome. (<b>A</b>) Correlation heatmap of the first 100 genes and top 50 metabolites between the CTPPPPD and control groups. (<b>B</b>) Correlation network of the top 100 pairs of genes and metabolites with significant differences between the CTPPPPD and control groups. (<b>C</b>) Venn diagram of KEGG pathway enrichment between the CTPPPPD and control groups. (<b>D</b>) Enrichment statistics for KEGG pathways of genes and metabolites in the CTPPPPD and control groups.</p>
Full article ">Figure 9
<p>CTPPPPD against NSCLC in central carbon metabolism in cancer and aminoacyl-tRNA biosynthesis pathway.</p>
Full article ">Figure 10
<p>The qRT-PCR-based analysis was conducted to assess the expression levels of 12 selected unigenes. (<b>A</b>) Genes involved in the PI3K-AKT pathway. (<b>B</b>) Genes involved in the MAPK pathway. (<b>C</b>) Genes involved in the P53 pathway. (<b>D</b>) Genes involved in the central carbon metabolism in cancer. *, **, *** and **** represent significant <span class="html-italic">p</span>-values ≤ 0.05, 0.01, 0.001, 0.0001, respectively.</p>
Full article ">Figure 11
<p>CTPPPPD molecular docking results for related proteins pertaining to central carbon metabolism in cancer. (<b>A</b>) Molecular docking diagram of FGFR3 (PDB code: 3GRW) vs. CTPPPPD. (<b>B</b>) Molecular docking diagram of FGFR3 (PDB code: 4K33) vs. CTPPPPD. (<b>C</b>) Molecular docking diagram of SESN2 (PDB code: 5CUF) vs. CTPPPPD. (<b>D</b>) Molecular docking diagram of PCK2 (PDB code: 5I67) vs. CTPPPPD. (<b>E</b>) Molecular docking diagram of TGF-β1 (PDB code: 5VQP) vs. CTPPPPD. (<b>F</b>) Molecular docking diagram of SLC2A1 protein (PDB code: 6THA) vs. CTPPPPD.</p>
Full article ">
16 pages, 1061 KiB  
Article
The Improvement of Adaptive Immune Responses towards COVID-19 Following Diphtheria–Tetanus–Pertussis and SARS-CoV-2 Vaccinations in Indonesian Children: Exploring the Roles of Heterologous Immunity
by Theresia Santi, Juandy Jo, Alida Roswita Harahap, Retno Asti Werdhani, Sri Rezeki S. Hadinegoro, Ivo Novita SahBandar, Ari Prayitno, Zakiudin Munasir, Yvan Vandenplas and Badriul Hegar
Vaccines 2024, 12(9), 1032; https://doi.org/10.3390/vaccines12091032 - 9 Sep 2024
Viewed by 346
Abstract
Background: Routine childhood vaccination, e.g., for diphtheria, tetanus, and pertussis (DTP), might provide additional protection against SARS-CoV-2 infection. This concept of heterologous immunity was explored in healthy children receiving both DTP and inactivated SARS-CoV-2 vaccines. Methods: A cross-sectional study was performed on 154 [...] Read more.
Background: Routine childhood vaccination, e.g., for diphtheria, tetanus, and pertussis (DTP), might provide additional protection against SARS-CoV-2 infection. This concept of heterologous immunity was explored in healthy children receiving both DTP and inactivated SARS-CoV-2 vaccines. Methods: A cross-sectional study was performed on 154 healthy children aged 6–8 years old in Jakarta, Indonesia. Their vaccination status for the DTP (including a diphtheria–tetanus booster vaccine at 5 years old) and CoronaVac (from 6 years old) vaccines were recorded. Peripheral blood samples were collected from all participants, in which anti-diphtheria toxoid IgG and anti-SARS-CoV-2 S-RBD antibodies and T cell-derived IFN-γ were measured. Results: The study participants with complete DTP vaccination had significantly higher titers of anti-diphtheria toxoid IgG than the ones without (median = 0.9349 versus 0.2113 IU/mL; p < 0.0001). Upon stratification based on DTP and CoronaVac vaccination statuses, the participants with complete DTP and CoronaVac vaccinations had the highest titer of anti-SARS-CoV-2 S-RBD antibodies (median = 1196 U/mL) and the highest concentration of SARS-CoV-2-specific T cell-derived IFN-γ (median = 560.9 mIU/mL) among all the groups. Conclusions: Healthy children aged 6–8 years old with complete DTP and CoronaVac vaccinations exhibited stronger SARS-CoV-2-specific T cell immune responses. This might suggest an additional benefit of routine childhood vaccination in generating protection against novel pathogens, presumably via heterologous immunity. Full article
Show Figures

Figure 1

Figure 1
<p>Time interval between the second dose of CoronaVac vaccine and laboratory assays measuring SARS-CoV-2-specific humoral and cellular immune responses. The data were obtained from 77 subjects who received DTP vaccination + booster and CoronaVac vaccination. The vertical axis is the time interval in months, and the horizontal axis is the absolute number of participants.</p>
Full article ">Figure 2
<p>Concentration of SARS-CoV-2-specific T cell-derived interferon gamma in serum of study participants. The study participants were classified into four groups based on their COVID-19 and DTP vaccination statuses: A (“COVID-19 yes/DTP yes”), B (“COVID-19 yes/DTP no”), C (“COVID-19 no/DTP yes”), and D (“COVID-19 no/DTP no”). The solid horizontal line within each box refers to the median value. The whiskers refer to the 10 and 90 percentile values, respectively. The Kruskal–Wallis test was performed to determine if there was a statistical difference among the four groups. If it was significant (<span class="html-italic">p</span> &lt; 0.05), Dunn’s multiple comparisons test was subsequently performed. The *** and ** indicate <span class="html-italic">p</span> &lt; 0.001 and <span class="html-italic">p</span> &lt; 0.01, respectively.</p>
Full article ">Figure 3
<p>Proposed mechanism of heterologous immunity induced by diphtheria–tetanus–pertussis vaccination in enhancing immune responses generated by inactivated SARS-CoV-2 vaccines in healthy children. (<b>A</b>) There are similar epitopes shared by the diphtheria–tetanus–pertussis vaccine and inactivated SARS-CoV-2 vaccine targets, particularly the SARS-CoV-2 spike protein. (<b>B</b>) Upon administration of the diphtheria–tetanus–pertussis vaccine or diphtheria–tetanus booster, certain peptide antigens will form peptide–MHC complexes to stimulate diphtheria-/tetanus-/pertussis-specific T cells. (<b>C</b>) Subsequently, upon administration of an inactivated SARS-CoV-2 vaccine, certain diphtheria-/tetanus-/pertussis-specific T cells will respond to certain antigens of the SARS-CoV-2 spike protein. This will generate a secondary immune response, resulting in heterologous immunity. (<b>D</b>) The heterologous immunity would also stimulate SARS-CoV-2 spike protein-specific T cells to produce various cytokines, including interferon gamma, at higher concentrations. (<b>E</b>) The activated CD4<sup>+</sup> T cells would stimulate specific B cells to mature and release immunoglobulins. This figure was created with <a href="http://BioRender.com" target="_blank">BioRender.com</a>.</p>
Full article ">
14 pages, 2389 KiB  
Article
MoMo30 Binds to SARS-CoV-2 Spike Variants and Blocks Infection by SARS-CoV-2 Pseudovirus
by Kenya DeBarros, Mahfuz Khan, Morgan Coleman, Vincent C. Bond, Virginia Floyd, Erick Gbodossou, Amad Diop, Lauren R. H. Krumpe, Barry R. O’Keefe and Michael D. Powell
Viruses 2024, 16(9), 1433; https://doi.org/10.3390/v16091433 - 7 Sep 2024
Viewed by 655
Abstract
MoMo30 is an antiviral protein isolated from aqueous extracts of Momordica balsamina L. (Senegalese bitter melon). Previously, we demonstrated MoMo30’s antiviral activity against HIV-1. Here, we explore whether MoMo30 has antiviral activity against the COVID-19 virus, SARS-CoV-2. MLV particles pseudotyped with the SARS-CoV-2 [...] Read more.
MoMo30 is an antiviral protein isolated from aqueous extracts of Momordica balsamina L. (Senegalese bitter melon). Previously, we demonstrated MoMo30’s antiviral activity against HIV-1. Here, we explore whether MoMo30 has antiviral activity against the COVID-19 virus, SARS-CoV-2. MLV particles pseudotyped with the SARS-CoV-2 Spike glycoprotein and a Luciferase reporter gene (SARS2-PsV) were developed from a three-way co-transfection of HEK293-T17 cells. MoMo30’s inhibition of SARS2-PsV infection was measured using a luciferase assay and its cytotoxicity using an XTT assay. Additionally, MoMo30’s interactions with the variants and domains of Spike were determined by ELISA. We show that MoMo30 inhibits SARS2-PsV infection. We also report evidence of the direct interaction of MoMo30 and SARS-CoV-2 Spike from WH-1, Alpha, Delta, and Omicron variants. Furthermore, MoMo30 interacts with both the S1 and S2 domains of Spike but not the receptor binding domain (RBD), suggesting that MoMo30 inhibits SARS-CoV-2 infection by inhibiting fusion of the virus and the host cell via interactions with Spike. Full article
(This article belongs to the Section Coronaviruses)
Show Figures

Figure 1

Figure 1
<p>(<b>A</b>) SARS2-PsV assay. This assay was conducted in triplicate, generating a dose–response curve measuring the viral inhibition of the crude (●) and ammonium sulfate precipitated extracts (<span style="color:#DE1077">■</span><span style="color:#00247D">)</span> of MoMo30 against SARS2-PsV. (<b>B</b>) XTT Cytotoxicity assay. The assay was conducted in tandem with the PsV assay with the percent cell viability compared with non-treated controls for each concentration shown. The (*) indicate statistically significant difference (<span class="html-italic">p</span> &lt; 0.05) in cytotoxicity between treated on non-treated controls. (<b>C</b>) SARS2-PsV assay of <span class="html-italic">M. balsamina</span> tannins. This is a dose–response curve measuring the viral inhibition of the isolated tannins against SARS2-PsV. Treatment concentrations range from 0 to 17.61 μg/mL. (<b>D</b>) XTT Cytotoxicity assay of <span class="html-italic">M. balsamina</span> tannins. Concentrations of tannins are in the same dose range. The (*) indicate statistically significant difference (<span class="html-italic">p</span> &lt; 0.05) in cytotoxicity between treated on non-treated controls. The assays were conducted in triplicate. The mean and SD are shown.</p>
Full article ">Figure 2
<p>Spike Variant ELISA. MoMo30 binds to the SARS-CoV-2 Spike glycoprotein Wu Han-1, Alpha, Delta, and Omicron BA.1 Spike variants. The assays were performed in triplicate. The mean and SD are shown.</p>
Full article ">Figure 3
<p>MoMo30 binds to full-length SARS-CoV-2 spike glycoprotein, the isolated S1 and S2 domains of Wu Han Spike, but not to the isolated receptor binding domain (RBD). The assays were done in triplicate. The mean and SD are shown.</p>
Full article ">Figure 4
<p>S1 Conformation Inhibition Hypothesis. The Spike protein consists of the S1 (light green) and S2 (dark green) domains. The RBD (yellow) adopts an “up” conformation when binding to the ACE2 receptor (pink) to allow viral attachment to the host cell. MoMo30 (blue) binds to the S1 domain such that the RBD is stuck in the “down” conformation and cannot attach to ACE2.</p>
Full article ">Figure 5
<p>S2 Conformation Inhibition Hypothesis. (<b>A</b>) Spike protein is cleaved by host cell proteases (represented with a pair of scissors) and releases the S1 domain. (<b>B</b>) MoMo30 binds the S2 domain and inhibits the necessary conformation changes in the S2 for fusion to occur.</p>
Full article ">Figure 6
<p>Protease Inhibition Hypothesis. (<b>A</b>) Spike protein is cleaved by host cell proteases along the boundary between the S1 and S2 domains. The release of the S1 domain exposes the fusion peptide within the S2. (<b>B</b>) MoMo30 blocks the cleavage by the proteases.</p>
Full article ">
Back to TopTop